Office-based blue laser therapy for inferior turbinate hypertrophy: a pilot study

PurposeTo investigate the subjective effect of office-based blue laser therapy for inferior turbinate hypertrophy in patients with nasal obstruction.MethodsPatients with nasal obstruction who underwent office-based blue laser for the inferior turbinate hypertrophy between October 2022 and December 2023 were included in the study. The two outcome measures used to gauge the improvement in nasal obstruction and success of surgery were the Nasal Obstruction Symptom Evaluation (NOSE) scale and the Visual Analogue Scale (VAS). Patient's level of comfort during the procedure was also rated using a 10-point VAS scale.ResultsA total of 14 patients were included in this study. The mean age of the study group was 41.47 +/- 18.52 and the F/M ratio was 4.67. All patients reported significant improvement in nasal breathing. The mean NOSE score decreased significantly from 13.07 +/- 3.89 pre-operatively to 2.64 +/- 2.43 post-operatively (p = 0.002). Similarly, the mean VAS score decreased from 7.43 +/- 0.85 to 2.0 +/- 1.57 (p = 0.002) following surgery. The procedure was well-tolerated by all participants and the mean total score ranged from 6 to 9 with an average of 7.59 +/- 1.34.ConclusionOffice-based blue laser therapy for inferior turbinate hypertrophy may be an effective treatment modality for nasal obstruction from the patient's perspective. Although the procedures were tolerated well with no complications noted, these results should be cautiously interpreted until studies using objective measures are conducted.